These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 31589789)
1. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer. Costigan DC; Dong F Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789 [TBL] [Abstract][Full Text] [Related]
2. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267 [TBL] [Abstract][Full Text] [Related]
3. Clinical validation of coexisting driver mutations in colorectal cancers. Zheng G; Tseng LH; Haley L; Ibrahim J; Bynum J; Xian R; Gocke CD; Eshleman JR; Lin MT Hum Pathol; 2019 Apr; 86():12-20. PubMed ID: 30481508 [TBL] [Abstract][Full Text] [Related]
4. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR. Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486 [TBL] [Abstract][Full Text] [Related]
5. Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. Grellety T; Gros A; Pedeutour F; Merlio JP; Duranton-Tanneur V; Italiano A; Soubeyran I Virchows Arch; 2016 Oct; 469(4):459-64. PubMed ID: 27401719 [TBL] [Abstract][Full Text] [Related]
6. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288 [TBL] [Abstract][Full Text] [Related]
7. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686 [TBL] [Abstract][Full Text] [Related]
9. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847 [TBL] [Abstract][Full Text] [Related]
10. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295 [TBL] [Abstract][Full Text] [Related]